-
公开(公告)号：US12084510B2
公开(公告)日：2024-09-10
申请号：US16797364
申请日：2020-02-21
发明人： Ilia Alexandre Tikhomirov , Maria L. Jaramillo , Maureen D. O'Connor-McCourt , Traian Sulea , Renald Gilbert , Bruno Gaillet , Jason Baardsnes , Myriam Banville , Suzanne Grothe
CPC分类号： C07K16/30 , C07K16/2863 , C07K2317/56 , C07K2317/565 , C07K2317/567
摘要： Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
-
公开(公告)号：US11945858B2
公开(公告)日：2024-04-02
申请号：US17056243
申请日：2019-05-17
发明人： Marzia Martina , Balu Chakravarthy , Yves Durocher , Mehdi Arbabi-Ghahroudi , Anne Marcil , Danica Stanimirovic , Traian Sulea , Maria Moreno , Umberto Banderali
CPC分类号： C07K16/18 , A61P29/00 , A61K2039/505 , C07K2317/22 , C07K2317/33 , C07K2317/565 , C07K2317/569 , C07K2317/92
摘要： The present disclosure concerns antibodies specific for the Na v.7 polypeptides which are capable of antagonizing the biological activity of the Na v.7 polypeptide. The anti-Na v.7 antibodies can be used for alleviating the symptoms of pain and/or for treating or alleviating the symptoms of an hyperproliferative disease. The presence disclosure also concerns immunogens and methods for making antibodies, such as the anti-Na v.7 antibodies, comprising a single-domain antibody.
-
公开(公告)号：US08574548B2
公开(公告)日：2013-11-05
申请号：US13654865
申请日：2012-10-18
CPC分类号： C07K14/71 , A61K47/665 , B82Y5/00 , C07K14/52 , C07K2319/32 , G01N2333/495
摘要： The invention provides multivalent ligand binding agents (traps) for members of the TGF-β superfamily and polypeptide linkers and methods for making and using such constructs. The traps may be used as therapeutic or diagnostic (imaging or non-imaging) agents for diseases/disorders caused by over-production/activity of the target ligand. In an embodiment of the invention there is provided a multivalent binding agent with affinity for a member of the TGF-β superfamily, the agent having the general structure I: ( -linker1)k-[{ -linker2- -linker3f-}n-( )m-(linker4- )d]h, where: n and h are independently greater than or equal to 1; d, f, m and k are independently equal to or greater than zero; bd's are polypeptide binding domains having an affinity for the same member of the TGF-β superfamily; and, linkers are unstructured polypeptide sequences.
摘要翻译： 本发明为TGF-β超家族和多肽接头的成员提供多价配体结合剂（陷阱）以及制备和使用这些构建体的方法。 陷阱可以用作由靶配体的过度生产/活性引起的疾病/病症的治疗或诊断（成像或非成像）试剂。 在本发明的一个实施方案中，提供了对TGF-β超家族的成员具有亲和性的多价结合剂，所述具有通式结构I：（
-
公开(公告)号：US20240101641A1
公开(公告)日：2024-03-28
申请号：US18457588
申请日：2023-08-29
摘要： The present invention relates, in general, to polypeptides capable of binding and neutralizing transforming growth factor beta (TGF-β) ligands, and uses of these polypeptides for treating disorders related to TGF-beta expression or activation (e.g. cancer and fibrotic diseases), and methods of making such molecules.
-
公开(公告)号：US11591408B2
公开(公告)日：2023-02-28
申请号：US16762672
申请日：2018-11-08
摘要： The present invention relates to compounds, compositions, and methods are provided for covalently linking a cargo molecule, such as a therapeutic or a diagnostic agent, to a glycan in the Fab region of an antibody. Also provided are methods of modeling and producing antibodies having de novo Fab glycosylation sites. Also provided are antibody carrier conjugates, methods of using the conjugates.
-
公开(公告)号：US11384141B2
公开(公告)日：2022-07-12
申请号：US17050072
申请日：2019-04-24
发明人： Gregory Hussack , Jamshid Tanha , Kevin Henry , Traian Sulea
IPC分类号： C07K16/18
摘要： The present document describes an antibody or an antigen-binding fragment that bind to serum albumin comprising three complementarity determining regions (CDR1, CDR2 and CDR3), for half-life extension of biologics. The present invention also relates to pharmaceutical compositions, nucleic acid vectors, cells comprising the nucleic acid vectors, and methods of removing molecules from serum.
-
公开(公告)号：US11091523B2
公开(公告)日：2021-08-17
申请号：US16461747
申请日：2017-11-17
申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education , National Research Council of Canada
IPC分类号： C07K14/495 , A61K38/00
摘要： Recombinant transforming growth factor (TGF)-β monomers modified to inhibit dimerization and block TGF-β signaling are described. The recombinant TGF-β monomers lack the ability to bind and recruit TGF-β type I receptor (TβRI), but retain the capacity to bind the high affinity TGF-β type II receptor (TβRII), and in some instances, include mutations that increase their affinity for TβRII. Nucleic acid molecules and vectors encoding the recombinant TGF-β monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-β monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-β monomers and/or cells producing the recombinant TGF-β monomers, to inhibit TGF-β signaling, such as to treat disorders associated with aberrant TGF-β signaling, are also described.
-
公开(公告)号：US10906973B2
公开(公告)日：2021-02-02
申请号：US16468960
申请日：2017-12-12
发明人： Danica Stanimirovic , Traian Sulea , Kristin Kemmerich , David Wilson , Jennifer Stratton , Matthew Pollard , Adam Clarke
摘要： The present invention relates, in general, to polypeptides capable of transmigrating the blood-brain barrier, and uses thereof. More specifically, the present invention relates to polypeptides derived by site-directed mutagenesis of an existing antibody fragment and uses thereof, and methods of making such molecules. The polypeptides of the present invention show enhanced blood-brain barrier crossing and brain exposure levels in vitro and in vivo.
-
公开(公告)号：US20190194349A1
公开(公告)日：2019-06-27
申请号：US16237363
申请日：2018-12-31
发明人： Ilia Alexandre Tikhomirov , Maria L. Jaramillo , Maureen D. O'Connor-McCourt , Traian Sulea , Renald Gilbert , Bruno Gaillet , Jason Baardsnes , Myriam Banville
IPC分类号： C07K16/32
CPC分类号： C07K16/32 , C07K2317/24 , C07K2317/565 , C07K2317/92
摘要： An erbB2 antibody is provided that binds preferentially to disease cells having an erbB2 density greater than a normal erbB2 density. The erbB2 antibody comprises a heavy chain and a light chain. Each chain has a constant region and a variable region. Each variable region comprises framework regions and complementarity determining regions (CDRs), wherein the CDRs have an amino acid sequence set forth below: For the heavy chain: CDR1 GFNIKDTYIH (SEQ ID No. 1) CDR2 RIYPTNGY57TR59YADSVKG (SEQ ID No. 2) CDR3 WGGDGFYAMDY (SEQ ID No. 3). For the light chain: CDR1 RASQDVN30TAVA (SEQ ID No. 4) CDR2 SASF53LYS (SEQ ID No. 5) CDR3 QQHY92TTPPT (SEQ ID NO. 6). At least one of Y57, R59, N30, F53, and Y92 is substituted by an amino acid that confers on said antibody a reduced erbB2 binding affinity (Kd) that is in the range from 0.1 nM to 100 nM. The substitution is other than N30A, F53N, Y92A and Y92F when there is a single substitution in the antibody light chain.
-
公开(公告)号：US20150044209A1
公开(公告)日：2015-02-12
申请号：US14365250
申请日：2012-12-14
申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY , THE NATIONAL RESEARCH COUNCIL OF CANADA
发明人： Pnina Brodt , Bernard Massie , Traian Sulea
IPC分类号： C07K14/71 , A61K39/395 , A61K35/28 , C07K16/22 , A61K45/06
CPC分类号： C07K14/71 , A61K35/28 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K48/00 , A61K2035/124 , A61K2039/505 , A61K2039/515 , C07K14/72 , C07K16/22 , C07K2319/01 , C07K2319/21 , C07K2319/30
摘要： There are described herein novel soluble IGF receptor Fc fusion proteins and compositions and methods of use thereof for treating angiogenesis associated disorders and malignant disease, such as cancer and metastasis, wherein the fusion proteins bind specifically to IGF-1 or IGF-2.
摘要翻译： 本文描述了新颖的可溶性IGF受体Fc融合蛋白及其用于治疗血管生成相关疾病和恶性疾病如癌症和转移的组合物及其使用方法，其中所述融合蛋白特异性结合IGF-1或IGF-2。
-
-
-
-
-
-
-
-
-
搜索结果
30 条记录 (耗时 0.034 秒)
